JW Holdings acquires world’s first Japanese approval for early pancreatic cancer testing technology

Published: 2018-06-11 17:15:49

Updated: 2018-06-11 17:15:49

JW Holdings was certified in novelty for its early pancreatic cancer diagnostic technology from the Japan Patent Office.

JW Holdings(CEO Sung-Kwon Han) announced on the 7^th that the company has acquired Japanese approval of its original technology for the world’s first ‘multi-biomarker/test kits,’ which allow users to test pancreatic cancer simply with the blood.

The JW Holdings’ original tec...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.